Helena Ullgren (Clinical Nurse Leader, Karolinska Institute, Sweden), Elin Backman Stålnacke (Oncology Contact Nurse, Karolinska Institute, Sweden), Rachel Powell (Advanced Clinical Practitioner, Haematology & Oncology, University Hospitals Birmingham NHS Foundation Trust, UK) and Patrick Jahn (University Hospital Halle, Halle, Germany) discuss managing EGFR inhibitor side effects in NSCLC.

This session focuses on the toxicity profile of EGFR-targeted therapies in non-small cell lung cancer (NSCLC), with a strong emphasis on skin-related adverse events and their broader impact on patients.

Experts highlight that dermatologic toxicities (rash, paronychia, fissures) are the most common and often the most distressing side effects. While not always clinically severe, these visible symptoms can significantly affect quality of life, body image, and psychosocial well-being, sometimes leading patients to pause or reduce treatment, impacting adherence.

The discussion also explores reactive management approaches, including topical treatments and collaboration with dermatology specialists, while noting that systemic corticosteroids are rarely required. Emerging evidence supports proactive regimens, reinforcing the importance of early intervention before toxicities worsen.

Beyond skin-related effects, the panel addresses other clinically relevant toxicities, including ocular issues, cardiac events, interstitial lung disease, and mucositis, which can be complex to assess, particularly in patients with pre-existing comorbidities.

A central theme is the importance of individualised, patient-centered care, recognising that toxicity impact goes beyond clinical grading and can significantly affect daily functioning, emotional well-being, and adherence.

The discussion concludes by highlighting the evolving role of digital health tools and remote monitoring, enabling closer follow-up, earlier intervention, and stronger nurse–patient communication.

Overall, this discussion reinforces that proactive management, multidisciplinary collaboration, and continuous patient engagement are critical to optimizing outcomes with EGFR-targeted therapies in NSCLC.